CohBar — HCW Conference September 2021
26 slides from CohBar's conference presentation, Sep 13, 2021
Slide 1: Breakthrough Mitochondrial Science: A Source for Novel Therapeutics
Breakthrough Mitochondrial Science A Source for Novel Therapeutics HCW Conference September 2021
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward - looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are based only on our current beliefs, expectations and assumptions regarding
Slide 3: CohBar Opportunity
3 CohBar Opportunity Leader in developing mitochondria based therapeutics • Novel approach leveraging over a billion years of evolution Recent clinical milestone • Positive CB4211 Phase 1a/1b topline data for lead candidate under development for NASH and obesity Near - term milestone • IND for CB513
Slide 4: Management Prior Experience
Management Prior Experience Joseph Sarret, MD, JD President & Chief Executive Officer 15+ years of leadership experience with public/private life sciences companies Held several executive management roles at companies ranging from early - to clinical - stage development and initial commercialization
Slide 5: CohBar is the leader in developing a new class of peptides
CohBar is the leader in developing a new class of peptides: Mitochondria based therapeutics 5 • Key insights by CohBar’s founders • Peptide sequences are encoded in the mitochondrial genome • Certain peptides regulate multiple organs and systems in the body • Published studies demonstrate broad effe
Slide 6: Pipeline
Pipeline MBT Programs Potential Indications Preclinical IND Enabling Activities Phase 1a Phase 1b Clinical CB4211 NASH Obesity Preclinical CB5138 - 3 IPF, Fibrotic Diseases Apelin Agonists ARDS, COVID - 19 ARDS CXCR4 Inhibitors Cancer, Other Diseases Immunotherapy Peptides Cancer Immunotherapy 6
Slide 7: Targeting opportunities with high unmet need
Targeting opportunities with high unmet need 7 • NASH and Obesity • US prevalence of NASH increasing – projected to be 27M by 2030 1 • Global NASH market size estimated to exceed $50B by 2027 2 • No approved treatment for NASH • Obesity impacts approximately one third of US adults • IPF and other fi
Slide 8: CB4211: Novel Mechanism of Action Relevant to NASH
SUBCUTANEOUS ADIPOSE TISSUE SYSTEMIC CIRCULATION PORTAL VEIN VISCERAL ADIPOSE TISSUE Splanchnic FFA Delivery HEPATOCYTE Targeting Free Fatty Acid Release from Fat Cells Inhibition/Regulation of Lipolysis • NALFD: excess free fatty acid released from abdominal fat cells by lipolysis - flows directly
Slide 9: CB4211 Phase 1a: Study Design and Subject Disposition
CB4211 Phase 1a: Study Design and Subject Disposition Phase 1a Study Design • Randomized, double - blind, placebo - controlled study • 6 cohorts of Single Ascending Dose (SAD) and 3 cohorts Multiple (7 - day) Ascending Dose (MAD) • Healthy adult volunteers (up to 8 per cohort) randomized (3:1) to CB
Slide 10: CB4211 Phase 1b: Study Design
CB4211 Phase 1b: Study Design CB4211 (25 mg QD SC) (n = 11) Placebo (n = 9) Baseline Week 4 Primary Endpoints: • Safety and tolerability Secondary Endpoint: • Pharmacokinetics Exploratory Endpoints: • Liver fat content (MRI - PDFF) • Body weight • Biomarkers of NASH and metabolic disease Screening •
Slide 11: Phase 1b Results: Changes in Key PD Biomarkers (Day 28)
Phase 1b Results: Changes in Key PD Biomarkers (Day 28) Biomarker CB4211 (25 mg) (n = 11) Placebo (n = 9) Difference from Placebo ALT (% reduction from baseline) - 21% 4% - 25%* Proportion of subjects with >17 U/L decrease in ALT (1) 27% 11% 16% AST (% reduction from baseline) - 28% - 11% - 17%* Glu
Slide 12: Phase 1b Results: CB4211 Significantly Reduced ALT and AST
Phase 1b Results: CB4211 Significantly Reduced ALT and AST Percent Change from Baseline in ALT CB4211 reduced ALT by 21% and AST by 28% at Week 4 0 1 2 3 4 -40% -30% -20% -10% 0% 10% Percent Change from Baseline in AST Weeks C h a n g e i n A S T * Placebo CB4211 Percent Change from Baseline in AST
Slide 13: Phase 1b Results: Comparison to Historical ALT Data
Phase 1b Results: Comparison to Historical ALT Data for 4 - Week Studies (1) CB4211 reduced ALT as much or more than other NASH candidates Parameter CB4211 (CohBar) (25 mg) (SC injection) MET409 ( Metacrine ) (50 mg) (oral) DUR - 928 ( Durect ) (300 mg) (IV injection) CRV43 ( Hepion ) (225 mg) (oral
Slide 14: Phase 1b Results: CB4211 Reduced Fasting Glucose Levels
Phase 1b Results: CB4211 Reduced Fasting Glucose Levels Percent Change from Baseline in Glucose CB4211 reduced fasting glucose by 6% at Week 4 0 1 2 3 4 -10% -5% 0% 5% Percent Change from Baseline in Glucose Weeks C h a n g e i n G l u c o s e # Placebo CB4211 Data are mean +/ - SEM. *Statistically
Slide 15: Phase 1b Results: Change from Baseline in Liver Fat Content
Phase 1b Results: Change from Baseline in Liver Fat Content (MRI - PDFF) Percent Absolute Reduction in LFC Placebo CB4211 -10% -8% -6% -4% -2% 0% -4.88% -5.03% Reduction in absolute LFC at Week 4 for CB4211 was comparable to other NASH candidates. However, liver fat content was also reduced in place
Slide 16: Phase 1a/1b Topline Safety Data: Positive Primary Outcome
Phase 1a/1b Topline Safety Data: Positive Primary Outcome Positive Results for Primary Outcome: Safety and Tolerability • CB4211 was well - tolerated and appeared safe with no serious adverse events • All adverse events were transient and generally mild to moderate • AEs occurring in >10% of subject
Slide 17: Phase 1b Topline Activity Data: Positive Exploratory Outcomes
Phase 1b Topline Activity Data: Positive Exploratory Outcomes Positive Results from Exploratory Trend Analysis at 4 Weeks • Robust and significant reductions in ALT, AST versus placebo • ALT reduction favorable vs other NASH candidates in 4 - week studies • ALT reduction predictive of potential bene
Slide 18: CB4211: Next Steps
CB4211: Next Steps • Continue to analyze data from Phase 1a / 1b trial • Plan to present additional data from this study at an upcoming scientific meeting • Continue ongoing work to optimize formulation towards commercial form • Complete necessary steps to move to Phase 2 (e.g., manufacturing, toxic
Slide 19: CB5138-3: IPF and other fibrotic diseases
CB5138 - 3: IPF and other fibrotic diseases • Demonstrated antifibrotic effects in cultured human cells o Decreased expression of fibrosis biomarkers in co - cultures of lung cells and fibroblasts o Inhibit pathological fibrotic process of conversion of fibroblasts to myofibroblasts in vitro • Anti
Slide 20: CB5138-3 Showed Efficacy as Monotherapy in Mouse Therapeutic Model of IPF
N o B l e o m y c i n V e h i c l e N i n t e d a n i b C B 5 1 3 8 - 3 5 0 1 2 3 4 Ashcroft Score Day 21 Bleomycin A s h c r o f t S c o r e * *** N o B l e o m y c i n V e h i c l e N i n t e d a n i b C B 5 1 3 8 - 3 5 0 1 2 3 4 Collagen Day 21 Bleomycin C o l l a g e n ( m g / m L ) * CB5138 - 3
Slide 21: CB5138 Efficacy in Mouse Therapeutic model of IPF
CB5138 - 3 Efficacy in Mouse Therapeutic model of IPF 21 Source: Cundy et al. Poster A2261; American Thoracic Society Meeting, August 5 - 10, 2020. CB5138 - 3 reduced fibrosis and inflammation in the mouse therapeutic IPF model. Representative photomicrographs from MT staining of lung tissue. A - al
Slide 22: CB5138-3 Monotherapy Reduced Key Pro-inflammatory Cytokines in BALF
0.0 0.5 1.0 1.5 2.0 2.5 MIP-1a at Day 21 M I P - 1 a ( p g / m L ) Control - No Bleomycin Vehicle Nintedanib CB5138-3 ** 0 20 40 60 MCP-1 at Day 21 M C P - 1 ( p g / m L ) Control - No Bleomycin Vehicle Nintedanib CB5138-3 * 0 200 400 600 IL-6 at Day 21 I L - 6 ( p g / m L ) Control - No Bleomycin V
Slide 23: Potential Milestones 2021 – 2022
Potential Milestones 2021 – 2022* 23 2H2021 • CB4211 • Initiate activities to support next CB4211 clinical study • Accelerate partnership discussions 2022 • CB5138 - 3 for IPF and other fibrotic diseases: File new IND and begin first in human clinical trial • Third clinical candidate: Select candida
Slide 24: Financial Summary (as of 6/30/21)
Financial Summary (as of 6/30/21) 24 • Capitalization • Shares outstanding: 62.3M; Fully diluted: 92.6M • Options: 10.9M, weighted average exercise price of $1.78 • Warrants: 19.4M, weighted average exercise price of $1.62 • Balance Sheet • Cash & investments: $13.8M; projected to last through Q2 20
Slide 25: CohBar Opportunity
25 CohBar Opportunity Leader in developing mitochondria based therapeutics • Novel approach leveraging over a billion years of evolution Recent clinical milestone • Positive CB4211 Phase 1a/1b topline data for lead candidate under development for NASH and obesity Near - term milestone • IND for CB51
Slide 26: @cohBar
@cohBar The